BETA
BETA
Madrigal Pharmaceuticals
MDGL50
$284.48arrow_drop_up0.36%$1.03
MDGL50
$284.48
arrow_drop_up0.36%Performance History
| Key Stats | |
|---|---|
| Open | $287.67 |
| Prev. Close | $283.45 |
| EPS | -23.14 |
| Dividend | Non-Dividend |
| Next Earnings Date | - |
| Dividend Yield % | - |
| PE Ratio | - |
| LOW | HIGH | |
|---|---|---|
| Day Range | 276.63 | 289.91 |
| 52 Week Range | 119.76 | 299.98 |
| Ratios | |
|---|---|
| Revenue | - |
| EBITDA Margin % | - |
| EPS | -23.14 |
Score Breakdown
Welcome to Stocklytics
Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.
Analyst Forecast
Period: Next 12 Months
•Analyst Ratings
••
Correlated Companies
About Madrigal Pharmaceuticals (MDGL)
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. Paul A. Friedman M.D.
- Headquarters
- West Conshohocken
- Employees
- 92
- Exchange
- NASDAQ
Keep an eye on Madrigal Pharmaceuticals
Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.
Frequently Asked Questions
help
What is Madrigal Pharmaceuticals 's (MDGL) price per share?
The current price per share for Madrigal Pharmaceuticals (MDGL) is $284.49. The stock has seen a price change of $1.03 recently, indicating a 0.36% change. This reflects the stock's recent market performance and investor sentiment.
help
What is the 52-week high and low for Madrigal Pharmaceuticals (MDGL)?
For Madrigal Pharmaceuticals (MDGL), the 52-week high is $299.98, which is 5.44% from the current price. The 52-week low is $119.76, the current price is 137.55% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.
help
Is Madrigal Pharmaceuticals (MDGL) a growth stock?
Madrigal Pharmaceuticals (MDGL) has shown an average price growth of 0.41% over the past three years. It has received a score of 93 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Madrigal Pharmaceuticals as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.
help
What is Madrigal Pharmaceuticals (MDGL) stock price performance year to date (YTD)?
As of the latest data, Madrigal Pharmaceuticals (MDGL) has a year-to-date price change of 25.4%. Over the past month, the stock has experienced a price change of 1.59%. Over the last three months, the change has been 46.36%. Over the past six months, the figure is 23.6%. Looking at a longer horizon, the five-year price change stands at 233.13%.
help
Is Madrigal Pharmaceuticals (MDGL) a profitable company?
Madrigal Pharmaceuticals (MDGL) has a net income of -$373.63M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 0% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. Operating income is noted at -$380.5M. Furthermore, the EBITDA is -$453.63M.
help
What is the market capitalization of Madrigal Pharmaceuticals (MDGL)?
Madrigal Pharmaceuticals (MDGL) has a market capitalization of $5.99B. The average daily trading volume is 293.03K, indicating the stock's liquidity and investor engagement.
News
VIKING THERAPEUTICS
EARNINGS
PIPELINE
NASH
OBESITY
7/19/2024Should Viking (VKTX) Stock be in Your Portfolio Pre-Q2 Earnings? - Zacks Investment Research
7/2/2024
Viking (VKTX) Skyrockets 197% YTD: Is the Stock Worth a Buy?
INVESTING
6/30/2024Is Madrigal Pharmaceuticals a Millionaire Maker?
INVESTING
6/28/2024Is Madrigal Pharmaceuticals Stock a Buy?
INVESTING
6/18/2024The Best Biotech Stock to Invest $1,000 in Right Now
INVESTING
6/16/2024Thinking of Buying Madrigal Pharmaceuticals Stock? Eli Lilly Would Like to Have a Word.
Sign up for our newsletter
Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.